The FDA has approved the following products:

• GlaxoSmithKline’s Entereg:
  

  Entereg (alvimopan) is a peripherally-acting mu opioid receptor (PAM-OR) antagonist designed to block the adverse side effects of opioid analgesics on the GI tract without blocking their beneficial analgesic effects.

• Tentative approval for Teva’s Lansoprazole, the generic equivalent of Prevacid.
• Tentative approval for both Cobalt Labs and Ivax’s Topiramate, the generic equivalent of Topamax.
• Tentative approval for Apotex’s Escitalopram oxalate, the generic equivalent of Lexapro.